Can You Really Trust City Forecasts For HSBC Holdings plc, GlaxoSmithKline plc and Vodafone Group plc?

Can City estimates for HSBC Holdings plc (LON: HSBA), GlaxoSmithKline plc (LON: GSK) and Vodafone Group plc (LON: VOD) be trusted?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

HSBC (LSE: HSBA), GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) and Vodafone (LSE: VOD) (NASDAQ: VOD.US) all look to be to be attractively priced based on City forecasts for the next two years. The problem is, City analysts can — and do — often get these forecasts wrong, which can sometimes leave investors in a sticky position.

Indeed, over the past year alone City analysts have reduced their earnings forecast figures for HSBC, Glaxo and Vodafone by a double-digit percentage. This leaves me wondering if there could be further reductions to come. 

Revising lower

cityHSBC, Glaxo and Vodafone are three FTSE 100 behemoths. Most investors will have at least one of these stalwarts in their portfolios. As all three companies currently support a dividend yield in excess of 4.5%, compared to the FTSE 100 average of less than 3.5%, they make a dependable backbone to build a portfolio around.

Still, investors should be careful, as the City has been reducing its earnings forecasts for these companies over the past year, which has pushed valuations higher.

Vodafone has been the most affected by these ‘moving forecasts’. This time last year the City was expecting Vodafone to report earnings per share of 29p during 2014, followed by earnings of 32p per share during 2015. These forecasts included Vodafone’s share of Verizon Wireless‘s income.

Excluding the Verizon Wireless income, and the share consolidation, the City was expecting Vodafone to report earnings per share of 9p during 2014 and then 10p during 2015. However, over the past few months these estimates have fallen further and the City now expects Vodafone to report earnings of  just 6.8p per share this year and 7.2p during 2015. 

Continual adjustment

Surprisingly, over the past year, Glaxo has seen its earnings forecasts adjusted lower by a shocking 34%! The City now expects the company to report earnings of 96p per share this year — this time last year earnings of 118p per share were expected. Similarly, 2015 forecasts have fallen from 130p per share down to 101p per share. 

HSBC has also seen its earnings forecasts revised lower, although the adjustment has only been less severe. For 2014, City analysts have adjusted the bank’s earnings lower from 62p per share, down to 54p per share. Further, 2015 earnings estimates have been downgraded by 10p, from 68p per share, to 58p per share. 

What does it mean?

How does it affect investors? Well, for a start falling earnings estimates have changed company valuations. Unfortunately, this could mean that investors see valuations change for the worse as analysts revise forecasts down further. 

However, dividend investors do not need to worry. In most cases City dividend forecasts are correct, as they are based on figures supplied by company management teams.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool recommends GlaxoSmithKline.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »